Aeterna Zentaris’ endometrial cancer drug fails in Phase III
admin 3rd May 2017 Uncategorised 0A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically significant increase in survival in patients taking the drug.
More: Aeterna Zentaris’ endometrial cancer drug fails in Phase III
Source: News